Impact of RNAi therapeutics on cardiac parameters in patients with hereditary transthyretin amyloidosis initially treated with stabilizers: A French real-world study
Archives of Cardiovascular Diseases · 2026-06 · 119 (6-7) · 452-460
DOI: 10.1016/j.acvd.2025.11.014 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Archives of Cardiovascular Diseases, 2026-06. Verfasst von Antoine Fraix und 15 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, CHRU Nancy, Site Brabois, 54500 Vandœuvre, France. Hauptthemen laut MEDLINE: Amyloid Neuropathies, Familial, Benzoxazoles, Cardiomyopathies, RNAi Therapeutics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alnylam Pharmaceuticals.
Abstract (Originalsprache)
BACKGROUND: Cardiomyopathy in hereditary transthyretin amyloidosis (ATTRv) is increasingly reported due to improved diagnostic techniques and increased clinician awareness. Optimal therapeutic strategies for mixed phenotypes remain challenging. AIMS: To describe the changes in cardiac parameters among patients with ATTRv and cardiac involvement who had switched from stabilizer monotherapy to ribonucleic acid interference (RNAi) therapeutics or added RNAi to stabilizer monotherapy (switching/adding RNAi). METHODS: Data from patients with ATTRv and confirmed cardiomyopathy who had started tafamidis monotherapy between 2010 and 2022 and switched to/added RNAi therapeutics (patisiran or vutrisiran) between 2018 and 2023 were retrospectively collected from October 2023 to May 2024. Functional, laboratory and imaging parameters were collected, and progression assessed according to the 2021 expert consensus on transthyretin amyloidosis with cardiomyopathy monitoring. RESULTS: Fifty patients (median [interquartile range] age 63 [58-70] years; 66% male) from 10 French centres were included. Mean±standard deviation follow-up durations on treatment were 3.8±2.7 years for tafamidis monotherapy and 2.5±1.9 years for RNAi (±tafamidis). Switching/adding RNAi was mainly for neurological progression (n=40; 80%). Under tafamidis monotherapy, 24% of patients worsened with simultaneous declines in clinical, laboratory and imaging parameters, while 76% were stable. After switching/adding RNAi, 90% of patients were stable, none worsened and 10% improved. CONCLUSION: This real-world French study is the first switch/add-on study in mixed phenotypes of ATTRv. It highlights the potential benefits of early switching/adding of RNAi in patients with insufficient cardiac response under tafamidis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cardiology Department, CHRU Nancy, Site Brabois, 54500 Vandœuvre, France.
- Referral centre for cardiac amyloidosis CERAMIC-Cardio, Cardiology Department, Bichat Hospital, AP-HP, 75018 Paris, France.
- Department of Cardiology, CHU de Toulouse, 31400 Toulouse, France; Department of Nuclear Medicine, CHU de Toulouse, 31400 Toulouse, France; Cardiac Imaging Centre, Medical School, CHU de Toulouse, Toulouse III Paul Saba…
- Department of Cardiology, Bichat University Hospital, AP-HP, 75018 Paris, France.
- Inserm, Reference Centre for cardiomyopathies, CIC 1413, Thorax Institute, CHU de Nantes, Nantes University, 44000 Nantes, France.
- Cardiology Department, La Timone Hospital, AP-HM, 264, 13005 Marseille, France.
Förderung
- Alnylam Pharmaceuticals
Zitieren
APA
Fraix, A., Algalarrondo, V., Lairez, O., Arnal, M., Piriou, N., Michaud, M., Habib, G., Roubille, F., Lucas, C., Duval, A. J., Bachelet, B., Donal, E., Damy, T., Réant, P., Kharoubi, M., & Huttin, O. (2026). Impact of RNAi therapeutics on cardiac parameters in patients with hereditary transthyretin amyloidosis initially treated with stabilizers: A French real-world study. Archives of Cardiovascular Diseases, 119(6-7), 452-460. https://doi.org/10.1016/j.acvd.2025.11.014
Vancouver
Fraix A, Algalarrondo V, Lairez O, Arnal M, Piriou N, Michaud M, et al. Impact of RNAi therapeutics on cardiac parameters in patients with hereditary transthyretin amyloidosis initially treated with stabilizers: A French real-world study. Archives of Cardiovascular Diseases. 2026;119(6-7):452-460. doi:10.1016/j.acvd.2025.11.014
BibTeX
@article{Fraix2026,
author = {Fraix, Antoine and Algalarrondo, Vincent and Lairez, Olivier and Arnal, Marie and Piriou, Nicolas and Michaud, Maud and Habib, Gilbert and Roubille, François and Lucas, Claire and Duval, Antoine Jobbé and Bachelet, Bérengère and Donal, Erwan and Damy, Thibaud and Réant, Patricia and Kharoubi, Mounira and Huttin, Olivier},
title = {Impact of RNAi therapeutics on cardiac parameters in patients with hereditary transthyretin amyloidosis initially treated with stabilizers: A French real-world study},
journal = {Archives of Cardiovascular Diseases},
year = {2026},
volume = {119},
number = {6-7},
pages = {452--460},
doi = {10.1016/j.acvd.2025.11.014}
}
EUVIMED